Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of PRL-8-53 and Unifiram — mechanism, side effects, legal status, and pricing.
PRL-8-53 is a non-peptide small-molecule aminoalkyl benzoic acid ester (methyl benzoate derivative), supplied as the hydrochloride salt. Originally characterized in 1974 animal studies as a spasmolytic and CNS-active agent, it has never been approved by any regulatory agency and is sold only as a research chemical. Exactly one published human trial exists—a 1978 double-blind study on verbal learning and retention—with no independent replication or modern safety data.
Unifiram (DM-232) is a synthetic non-peptide small-molecule nootropic structurally related to sunifiram, though not a racetam itself. It originated from Italian academic research (University of Florence) in the early 2000s and has never progressed beyond preclinical animal studies; it is not an approved or investigational drug in any regulatory database. Unifiram is sold openly by research-chemical vendors as an unregulated laboratory reagent. No human data of any kind exist.
PRL-8-53
Unifiram
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
PRL-8-53
Unifiram
COA corpus from Disclosed Labs — independently tested batches only.
PRL-8-53
3
COAs
96.8%
Avg purity
2
Labs
Unifiram
1
COAs
99.4%
Avg purity
1
Labs
Exactly one published human study was located: a 1978 double-blind trial (Hansl & Mead, <em>Psychopharmacology</em>, PMID 418433) using the serial anticipation method to test oral PRL-8-53 on verbal learning acquisition and retention, with follow-up on visual reaction time and motor control; the study reported statistically significant retention improvement (most P<0.01) and no significant reaction-time or motor effects, but sample size and exact dose are not stated in the available abstract. No further human trials were found, and no ClinicalTrials.gov entries exist. Preclinical work is limited to the 1974 Hansl paper (PMID 4824605) in dogs and rats, indexed for avoidance learning, conditioning, memory, and pharmacological interaction with apomorphine and methamphetamine, though full quantitative findings could not be verified because no abstract text is available.
No human data of any kind exist for unifiram; no registered clinical trials or published human studies were found. All available evidence is from rodent behavioral and in-vitro electrophysiology studies. In mice and rats, unifiram (0.001–1 mg/kg i.p. or 0.01–0.1 mg/kg oral) reversed amnesia induced by scopolamine, mecamylamine, baclofen, clonidine, and NBQX in passive-avoidance and Morris water-maze tests, at doses roughly 1,000-fold lower than piracetam, without impairing motor coordination or altering spontaneous locomotor activity. No systematic toxicology (repeat-dose, genotoxicity, carcinogenicity) studies have been published.
PRL-8-53 and Unifiram are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs